72 completed, 25 unknown, 9 terminated, 6 active not recruiting. 54 Phase 3, 46 Phase 2, 8 Phase 1, 2 Not applicable, 1 Phase 4.
Follow Tamoxifen Citrate: new trials by email Literature Review of Tamoxifen Citrate trials Research Report on Tamoxifen Citrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor Method(s)1 Attribution, Method(s)2 Attribution, - Metastatic Breast Cancer, Tumor | Unknown | DR. DIANE CHISESI NFS. MD. PHD. | 100 | 2024-07-01 | 2023-12-04 | |
| Tamoxifen Therapy for Myotubular Myopathy ApoTamox 10mg, Placebo - X Linked Myotubular Myopathy | Phase 1 / Phase 2 | Terminated | James Dowling | 6 | 2020-12-18 | 2024-09-19 |
| A Study of TY-302 in Patients With Advanced Solid Tumors TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg - Breast Cancer, Solid Tumor | Phase 1 | Unknown | TYK Medicines, Inc | 60 | 2020-12-07 | 2022-12-07 |
| Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Tamoxifen Citrate - Breast Cancer Female, Hormone Receptor Positive Tumor | Phase 2 | Active not recruiting | British Columbia Cancer Agency | 290 | 2019-09-23 | 2023-06-15 |
| The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer Tamoxifen Citrate, Letrozole, Exemestane - Breast Cancer | Phase 2 | Completed | Johns Hopkins University | 30 | 2019-02-20 | 2024-05-07 |
| Breast Cancer Treatment Based on Organ-like Culture Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride - Breast Cancer Organoids | Unknown | Xijing Hospital | 300 | 2019-01-02 | 2019-04-24 | |
| Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Anastrozole, Exemestane, Laboratory Biomarker Analysis - HER2/Neu Negative, Invasive Breast Carcinoma | Phase 4 | Withdrawn | Fred Hutchinson Cancer Center | 2018-09-01 | 2018-12-27 | |
| Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer Tamoxifen, Toremifene - Breast Cancer Female | Phase 3 | Unknown | Chinese Anti-Cancer Association | 844 | 2017-11-01 | 2017-11-22 |
| Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Afimoxifene, Laboratory Biomarker Analysis, Placebo - Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive | Phase 2 | Completed | Northwestern University | 100 | 2017-05-31 | 2024-12-18 |
| Tamoxifen in Patients With Oesophageal Cancer Tamoxifen - Cancer, Gastrointestinal Neoplasms | Phase 1 | Unknown | University of Nottingham | 20 | 2015-12-01 | 2017-05-09 |
| Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 81 | 2015-05-28 | 2026-10-26 |
| Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors Tamoxifen Citrate - Bladder Cancer | Phase 2 | Completed | Baylor College of Medicine | 15 | 2015-04-01 | 2021-01-13 |
| Phase II Study of Everolimus Beyond Progression everolimus, anastrozole, letrozole - Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Terminated | Emory University | 3 | 2014-11-25 | 2022-04-05 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer anastrozole, everolimus, exemestane - Breast Cancer | Phase 3 | Active not recruiting | SWOG Cancer Research Network | 1939 | 2013-09-12 | 2026-10-23 |
| Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Neoadjuvant Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis - Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ | Not applicable | Completed | Virginia Commonwealth University | 59 | 2011-04-01 | 2016-07-12 |
| Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline citalopram hydrobromide, escitalopram oxalate, gabapentin - Breast Cancer, Depression | Completed | Mayo Clinic | 88 | 2011-03-16 | 2025-02-14 | |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Anastrozole, Exemestane, Laboratory Biomarker Analysis - Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 5018 | 2011-02-28 | 2026-10-26 |
| Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer tamoxifen - Breast Cancer, Stage IV Breast Cancer | Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 124 | 2011-01-07 | 2023-06-29 |
| Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors Tamoxifen Citrate, Placebo, Digital mammography - Breast Cancer | Phase 2 | Active not recruiting | University of Alabama at Birmingham | 84 | 2010-09-01 | 2026-01-05 |
Showing 20 of 113. Sign in to see all of them.
Breast Neoplasms (88) · Breast Carcinoma In Situ (13) · Carcinoma, Intraductal, Noninfiltrating (13) · Breast Neoplasms, Male (7) · Inflammatory Breast Neoplasms (6) · Central Nervous System Neoplasms (5) · Glioblastoma (4) · Gliosarcoma (4) · Astrocytoma (3) · Brain Neoplasms (3) · Carcinoma, Ovarian Epithelial (3) · Endometrial Neoplasms (3) · Glioma (3) · Neoplasms (3) · Carcinoma, Ductal, Breast (2)
National Cancer Institute (NCI) (15) · Scottish Cancer Therapy Network (6) · ETOP IBCSG Partners Foundation (5) · Fred Hutchinson Cancer Center (4) · SWOG Cancer Research Network (4) · Institute of Cancer Research, United Kingdom (3) · NCIC Clinical Trials Group (3) · San Diego Pacific Oncology & Hematology Associates (3) · Case Comprehensive Cancer Center (2) · City of Hope Medical Center (2) · Eastern Cooperative Oncology Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · International Collaborative Cancer Group (2) · Mayo Clinic (2) · NSABP Foundation Inc (2)
United States (66) · United Kingdom (24) · Canada (18) · France (9) · Italy (7) · Switzerland (7) · Australia (6) · Belgium (5) · Ireland (5) · Puerto Rico (5) · Germany (4) · New Zealand (4) · South Africa (4) · China (3) · Hungary (3)
Edward F. McClay, MD (3) · W.D. George, MD, MS, FRCS (3) · Barbara L. Smith, MD, PhD (2) · Brenda W. Cooper, MD (2) · Clifford A. Hudis, MD (2) · Daniel Rea, MD (2) · Gini Fleming (2) · James N. Ingle, MD (2) · R. Charles Coombes, MD, MRCP, FRCP, PhD, FMedSci (2) · Robert Paridaens, MD, PhD (2) · Vered Stearns, MD (2) · Agustin Garcia, MD (1) · Anthony Howell (1) · Anthony Michalski, MD (1)
PMID 26276354, PMID 39621968, PMID 10076722, PMID 10210538, PMID 10458221, PMID 10663329, PMID 12610186, PMID 14760111, PMID 15014181, PMID 15501952, PMID 15709195, PMID 16236738, PMID 16344321, PMID 16382061, PMID 16421418, PMID 16443947, PMID 16730270, PMID 17200148, PMID 17267326, PMID 17301074, PMID 17307102, PMID 17404368, PMID 17405995, PMID 17405996, PMID 17492927, PMID 17679725, PMID 17912636, PMID 17998546, PMID 18025439, PMID 18083065, PMID 18279765, PMID 18316672, PMID 18332471, PMID 18420499, PMID 18794551, PMID 18952561, PMID 18981464, PMID 19096768, PMID 19218306, PMID 19243946, PMID 19332727, PMID 19364653, PMID 19468030, PMID 19474112, PMID 19528136, PMID 19692688, PMID 20004966, PMID 20012355, PMID 20144231, PMID 20385495
U10CA032102 (5), P30CA043703 (3), U10CA180821 (3), P30CA033572 (2), P30CA060553 (2), U10CA021115 (2), U10CA027469 (2), U10CA031946 (2), U10CA180868 (2), 2004 (1), 2005 (1), 2008 (1), K23CA160664 (1), N01CN00035 (1), N01CN35157 (1)